Following identification of the proportion of pelvic congestion among symptomatic patients complaining of chronic pelvic pain, and in a totally asymptomatic group of patients requesting tubal ligation, the efficiency of goserelin acetate versus medroxyprogesterone acetate was compared objectively using pelvic venogram scores, and subjectively by symptom resolution, improvement of psychological status and sexual functioning in a prospective randomized trial in 47 patients with pure pelvic congestion syndrome. Patients received either goserelin acetate (3.6 mg/month for 6 months) or medroxyprogesterone acetate (MPA; 30 mg/day for 6 months). Among patients with chronic pelvic pain, those with pure pelvic congestion were mostly parous, had the most severe pelvic signs and symptom scores, lowest rates of sexual functioning, and higher states of anxiety and depression as compared with others. At 1 year after treatment, goserelin remained superior to MPA in terms of pelvic venographic improvement as an objective measure. In alleviation of signs and symptomatology, improvement of sexual functioning and reduction of anxiety and depressive states as subjective measures, goserelin acetate achieved a statistically significant advantage (P ⍧ 0.0001) compared with MPA.
Introduction
Currently, it is not clear whether congestion is a result of ovarian dysfunction or mechanical factors. Proponents of The pelvic congestion syndrome is a distinct clinical entity ovarian dysfunction claim that induced or natural hypowhich is often overlooked in everyday practice (Beard et al., oestrogenic hormonal milieu results in the diminution of 1986; Porpora and Gomel, 1997; Venbrux and Lambert, 1999) .
varicose vein diameters. It has been suggested that oestrogen Although this syndrome has been intermittently recognized for is a venous dilator, and that hypo-oestrogenic states or many years, its aetiology is unclear, and proposed treatments antagonizing the effects of oestrogen by progesterone results are not uniform. In 1949, there seemed no doubt that this in resolution of symptoms (Farquhar et al., 1989 ; Reginald syndrome was a stress disorder (Taylor, 1949a (Taylor, -c), but by et al., 1989 Adams et al., 1990) . On the other hand, according 1964 opinion had changed (Lefevre, 1964) . Despite the early to the mechanical theory which is easy to speculate, a 60-fold observations of Lefevre, clinicians who did not include increase in the capacity of pelvic veins during successive late venography in the evaluation armamentarium of chronic pelvic pregnancies makes these vessels vulnerable, and eventually pain continued to refer these patients for psychotherapy, with leads to vascular incompetence, resulting in dilatation of a presumed diagnosis of undetectable organic pathology (Beard veins and retrograde vascular flow in the non-pregnant state et al., 1986) . (Reginald et al., 1987; Sichlau et al., 1994) . It is probable that During the past two decades, a number of authors have both of these hypotheses of aetiology are cooperative (Hobbs, reintroduced peruterine venography in addition to ultrasound 1990) . The cause of pain due to the pelvic congestion remains and diagnostic laparoscopy to evaluate chronic pelvic pain unclear, but the most likely possibility is that increased patients (Beard et al., 1984 (Beard et al., , 1986 . These studies have shown dilatation, concomitant with stasis, leads to the release of local that pelvic congestion syndrome is responsible for pain in a pain-producing substances (Beard et al., 1986; Reginald et al. , high proportion of patients with no detectable organic pathology 1989; Porpora and Gomel, 1997; Venbrux and Lambert, 1999) . (Beard et al., 1984 (Beard et al., , 1986 Adams et al., 1990; Venbrux and Lambert, 1999) .
In the past, medroxyprogesterone acetate (MPA) has been used to suppress ovarian function of pelvic congestion syndrome patients, and proved to be effective. It was shown that MPA given at 30 mg/day for 6 months was effective in terms of objective (venography) and subjective (pain) improvement, both during and immediately after treatment of pelvic congestion syndrome. In another trial, long-term benefits (9 months after the end of treatment) of MPA (30 mg/day for 4 months) and psychotherapy on subjective outcome measures were demonstrated. Gonadotrophin-releasing hormone (GnRH) agonists, combined with hormone replacement therapy (HRT), have been used for the treatment of this syndrome (Gangar et al., 1993) . These authors reported that, after a treatment period of 4 months, combined goserelin and HRT was not effective in the treatment of pelvic congestion syndrome, despite effective ovarian suppression. Since 1994, pelvic venography has been used in our institution as a diagnostic tool in combination with other established modalities such as laparoscopy and transvaginal ultrasonography to determine the aetiology of chronic pelvic pain.
The purposes of this prospective randomized trial in patients with pure pelvic congestion were first, to identify the proportion of venographically proven pelvic congestion both in a group of ency of the GnRH analogue goserelin acetate and MPA was compared objectively by obtaining pelvic venogram scores, and subjectively by monitoring symptom resolution, improvement congestion (cases without any other detectable organic pathology other than pelvic congestion) in a prospective randomized manner. This of psychological status, and sexual functioning.
investigation was conducted in the teaching department of a university medical centre, the trial protocol having been approved by the Ethics
Materials and methods
Committee of the institution. All subjects gave their informed consent before entering the study. This prospective trial was undertaken between March 1996 and March 2000, and designed to serve two purposes: (i) to identify the proportion During this study, 148 patients complaining of chronic pelvic pain were prospectively evaluated by adherence to a strict protocol that of venographically proven pelvic congestion in chronic pelvic pain patients, as well as in asymptomatic patients requesting tubal ligation; consisted of pelvic examination, venography, laparoscopy, ultrasonography and questionnaires to determine psychological status and sexual and (ii) to assess the effect of two different regimens [MPA 30 mg/day for 6 months, and goserelin acetate (Zoladex; Zeneca, Macclesfield, functioning. The existence of pelvic congestion or other pertinent abnormality in 30 asymptomatic patients requesting sterilization was UK) 3.6 mg for six monthly injections] in the treatment of pure pelvic Mean and 95% confidence interval for venography score, pelvic symptom score, HADS score (Anxiety, Depression, Total) and revised Sabbatsberg Sexual Rating Scale (rSSRS) score of study subjects.
investigated using venography and ultrasonography before laparoscopy.
were assessed by the same physicians. All patients were asked to complete the submitted forms of the Hospital Anxiety and Depression These patients were also requested to complete the questionnaires.
All patients in the study underwent peruterine venography, highScale (HADS) (Zigmond and Snaith, 1983) , and the revised Sabbatsberg Sexual Rating Scale (rSSRS) (Garrat et al., 1995) . resolution transvaginal and/or transabdominal ultrasound examination and diagnostic laparoscopy. Pelvic symptoms and physical findings
Grading of symptoms and physical findings were assessed at each clinic visit on a modification of a published scale (Biberoglu and was assigned a value of 1. In moderate congestion, the veins were of variable calibre and tortuous, and difficult to discern individually (value Behrman, 1981) that was modified by excluding induration. Pelvic pain, dyspareunia, dysmenorrhoea and pelvic tenderness were each scored of 2). In extensive congestion, the veins were wide, obscured by a pool of contrast medium around the ovarian plexus, showed great variation as: none (0 points); mild (1); moderate (2); and severe (3). The sum in calibre, and appeared highly tortuous (value of 3). Thus, a total score of these variables comprised the total pelvic symptom score in this of 3 indicated a normal venogram, while a score of 9 indicated the most study. The scale and its scoring (and modifications of it) have been abnormal venogram. A venogram score of ജ5 was found to be an used frequently as a reliable tool in the assessment of pelvic pain.
objective measure of pelvic congestion with a high sensitivity (91%) In all cases, peruterine venography was performed before diagnostic and specificity (89%) (Beard et al., 1984 (Beard et al., , 1986 . In this trial, all patients laparoscopy in the first week after menses. Fluoroscopic screening was (controls, organic pain, pure pelvic congestion) were assessed according performed to observe the spread of contrast material into myometrial, to the above-mentioned scoring system. A venography score of ജ5 was uterine and ovarian venous plexuses. Routine films were taken at the accepted as a threshold to diagnose pelvic congestion. To improve end of injection, and 20 and 40 s later. Peruterine venographies were the comparison and the perspective, three venograms from different assessed by a pelvic venogram scoring system (Beard et al., 1986) , patients were presented, each showing successive deterioration in according to which ovarian vein dilatation, dye disappearance and ovarian vein diameter and ovarian plexus at the right side (Figure congestion are considered as three variables. Each variable is assigned 1). During the performance of the venography, the ovarian plexus a value of 1 to 3, depending on the degree of abnormality. Ovarian is straightened by a strong downward traction of the tenaculum for vein diameter was measured at the point of maximum diameter of the purposes of demonstration. segment of the vein that could be clearly visualized. If the diameter was High-resolution ultrasound examinations were carried out using Ͻ4 mm, it was assigned a value of 1, 5-8 mm a value of 2, and Ͼ8 mm commercially available instruments. The investigators were aware of a value of 3. The disappearance interval was determined from the films the physical changes in the pelvic organs (uterine and endometrial taken at the end of injection, and at 20 and 40s after injection. When changes, cystic ovaries) of women with pelvic congestion (Taylor, the dye disappeared at the end of injection, it was assigned a value of 1949a,b,c; Adams et al., 1990) . However in this study, the aim of 1; when the time was Ͼ20 s it was valued as 2, while a time Ͼ40 s was the sonography was to examine the detailed internal consistency of valued as 3. Congestion was assessed from the calibre and the tortuous the uterus and adnexa in order to detect, suspect or exclude organic appearance of individual pelvic veins. Normally, the veins are small, pathology such as myoma, adenomyosis, endometrioma and hydrostraight, similar in calibre, and easily visualized. Such an appearance salpinx. General endotracheal anaesthesia was used in all patients for multiple puncture diagnostic laparoscopy. Those in the control group were sterilized by bipolar electrocoagulation; patients with organic Table II . Clinical characteristics of randomized subjects by allocated pathology other than pure pelvic congestion, were appropriately treated treatment a in the same session via laparoscopy or laparotomy.
The HADS is a self-assessment mood scale designed specifically for use in non-psychiatric hospital outpatients to determine states of anxiety Age (years) 32 . of severity of these mood disorders in patients under investigation in HADS ϭ Hospital Anxiety and Depression Scale; MPA ϭ medroxyprogesterone acetate; rSSRS ϭ revised Sabbatsberg Sexual Rating Scale.
medical and surgical departments. Its validity and reliability have been tested in the present patient population. In the present study, HADS in order to assess the impact of interventions on sexual functioning within clinical trials (Garrat et al., 1995) . The validity and reliability of was used to diagnose, and to assess the states of anxiety and depression, as well as to determine the impact of treatment on health-related quality this scale have been demonstrated and tested in the present patient population. of life.
The rSSRS is a 12-item questionnaire for the assessment of sexual The submitted HADS and rSSRS forms were interpreted by one of the authors (S.O.) in a different psychiatry department in a different functioning (Garrat et al., 1995) . For each item, there are five possible answers, scored from 0 to 4 points (from the lowest to the highest city. During interpretation, she was blinded to the patients and treatment, and was unaware of the venography scores and pelvic symptom scores. sexual satisfaction). The scores of 12 items are then summed and transformed to a scale of 0 to 100. Scores between these values represent
In parallel with evaluating and gathering data from chronic pelvic pain patients, those with pure pelvic congestion were randomized prothe percentage of the total possible score achieved. This scale has the potential to be widely used as an adjunct to clinical measures of health spectively to treatment arms of goserelin or MPA. Thus, all patients with pure pelvic congestion had pretreatment objective venogram scores, subjective pelvic pain scores, and pre-filled questionnaire of rSSRS and HADS. and rSSRS were re-evaluated for residual pelvic findings, sexual response and for mood as subjective outcome variables at 12 months after treatment. None of the patients with pure pelvic congestion had psychotherapy as an adjunct to medications. None of them used oral contraceptives after the original treatment as an adjunctive measure. At the final evaluation during the performance of peruterine venography the operators were blinded.
Statistical analysis
Statistical analysis was performed using SPSS for Windows 6.0. Variables were compared statistically using the Mann-Whitney U-test, Wilcoxon test and Friedman two-way ANOVA where appropriate. A P-value of Ͻ 0.05 was considered to be significant.
Results
By strict adherence to the protocol for diagnostic evaluation of chronic pelvic pain, organic pathology was detected in 93 of 148 patients, 11 of whom had concomitant pelvic congestion (venography score Ͼ5) (Figure 2a-c) . The most common organic pathology detected was endometriosis (n ϭ 58, 39%), followed by chronic pelvic inflammatory disease (PID) (n ϭ 17, 11%), postoperative adhesions (n ϭ 15, 10%), uterine disease (myoma, n ϭ 4, 2.7%; adenomyosis, n ϭ 1, Ͻ1%), AllenMasters syndrome (n ϭ 1, Ͻ1%) and ovarian mass (n ϭ 1 dermoid cyst, Ͻ1%). In the group in which organic pathology was detected, concomitant pelvic congestion was observed in 11 patients (12%). Those patients with concomitant congestion were observed in five cases of endometriosis, four of PID, one case with myoma, and one case with adenomyosis. for disease (ultrasonographic examination, venography and laparoscopy were all normal in this subset of patients) and HADS statistically significant improvement in subjective outcome measures in both arms (Table III) . However, this improvement scores relevant for depression (HADS depression subscale was ജ12). Among the patients with depression, a strikingly high was found to be statistically not consistent in the MPA arm at the end of 12 months treatment. Even though MPA was still HADS depression subscale was noted, a normal venogram score, and a high pelvic symptom score in addition to diminished significantly effective in improving the subjective outcome of patients at the final evaluation, as time progressed the positive sexual functioning. In the group of asymptomatic patients (those requesting tubal ligation), only a single case of mild pelvic effects of MPA on subjective outcome measures declined in a statistically significant manner. In the MPA arm, mean pelvic congestion with a venography score of 4 was detected, whereas there were two cases of adhesive disease, three of minimal symptom score, after declining to 5.1 Ϯ 1.3 from baseline, rose to 6.2 Ϯ 1.1 (P ϭ 0.0004). The HADS anxiety subscale score endometriosis, and one case with a small myoma.
The baseline clinical characteristics and mean pelvic pain, did not change significantly from the first evaluation to the final one (5.5 Ϯ 1.1 versus 5.6 Ϯ 1.1; P ϭ 0.42). However, the HADS venography, rSSRS and HADS scores of all patients are listed in Table I . The mean and 95% confidence interval for venography depression subscale, after declining to 4.4 Ϯ 0.8 from baseline, rose to 4.8 Ϯ 0.9 (P ϭ 0.0026), and the total HADS score, after score, pelvic symptom score, HADS score (anxiety, depression, total) and rSSRS score of study subjects are given in Figure 3 . declining to 9.9 Ϯ 1.6 from baseline, rose to 10.3 Ϯ 1.7 (P ϭ 0.033). The same deterioration was noted in the rSSRS scores The parity (mean Ϯ SD) of patients with pelvic congestion syndrome was higher than the parity of those with organic which, after improving to 71.7 Ϯ 7.3 from baseline, declined to 66.4 Ϯ 8.3 (P ϭ 0.0001). In contrast, the improvement of pathology (3.4 Ϯ 1.3 versus 2.8 Ϯ 1.3; P ϭ 0.0001), whereas statistically significant difference of parity was seen among subjective outcome measures in the goserelin arm did not change as time progressed from the end of treatment to 12 months after patients requesting tubal ligation as compared with pelvic congestion syndrome. Even though patients with organic pathology treatment. In the goserelin arm, none of the variables showed a statistically significant change from the end of treatment to 12 had venography scores significantly higher (4.6 Ϯ 1.5 versus 3.2 Ϯ 0.5; P ϭ 0.0001) than those requesting tubal ligation, their months after treatment. At the final evaluation (12 months from the end of treatment), venography scores were significantly lower (8.6 Ϯ 0.5 versus 4.6 Ϯ 1.5; P ϭ 0.00001) than those with pure pelvic congestion.
although both agents were effective in the treatment of pure pelvic congestion syndrome (venography score reduction, Pelvic symptom scores were significantly higher in those patients with pelvic congestion syndrome as compared with those pelvic symptom score reduction, HADS score reduction and rSSRS score improvement) (Table III) , a statistical comparison patients with organic pathology (10.5 Ϯ 1.3 versus 6.7 Ϯ 1.8; P ϭ 0.00001). HADS scores of patients with pelvic congestion of these agents pointed to a better outcome for goserelin (Table  IV) . Goserelin was shown statistically to be more effective in syndrome were significantly higher among all patients. Significantly higher total HADS scores of 13.7 Ϯ 1.4 were noted for reducing pelvic venography score (Figure 4a ,b) than MPA (∆ mean scores 4.2 Ϯ 0.9 for MPA and 5.3 Ϯ 0.7 for goserelin; patients with pure pelvic congestion as compared with total HADS scores of 10.6 Ϯ 2.1 for patients with organic pathology P ϭ 0.0002). Goserelin proved also to be more effective in decreasing pelvic symptom score (∆ mean score 4.7 Ϯ 1.4 for (P ϭ 0.0001); the significantly elevated scores were also observed in anxiety and depression subscale scores (anxiety MPA, 7.7 Ϯ 1.8 for goserelin; P ϭ 0.00001). Goserelin was also statistically more efficient in decreasing HADS anxiety subscale subscale score 7.4 Ϯ 0.9 versus 5.7 Ϯ 1.4; P ϭ 0.0001; depression subscale score 6.3 Ϯ 1.02 versus 4.9 Ϯ 1.3; P ϭ 0.0001 for and total scores, whereas in decreasing the depression subscale of HADS scores both agents were similarly effective [∆ mean patients with pure pelvic congestion syndrome as compared with those patients with organic pathology respectively). The rSSRS score 1.6 Ϯ 1.2 for MPA, 2.6 Ϯ0.8 for goserelin (P ϭ 0.002); for depression subscale ∆ mean score 1.6 Ϯ 1.3 for MPA, scores were significantly lower in patients with pelvic congestion syndrome than in those with organic pathology (18.1 Ϯ 4.1 1.9 Ϯ 0.9 for goserelin (P ϭ NS); for HADS total score ∆ mean 3.3 Ϯ 1.9 for MPA, 4.6 Ϯ 1.1 for goserelin (P ϭ 0.002)]. versus 33.9 Ϯ 10.1; P ϭ 0.0001). As expected, significantly lower scores of HADS and higher scores of rSSRS were noted Goserelin improved rSSRS scores more efficiently than MPA (∆ mean score 47 Ϯ 7.8 for MPA, 62.5 Ϯ 5 for goserelin; in patients requesting tubal ligation.
After identification, 47 patients with pure pelvic congestion P ϭ 0.00001). were randomized to receive either goserelin or MPA for 6 months. At the start of treatment, the groups were comparable Discussion in terms of age, parity, venography scores, pelvic symptom scores and HADS and rSSRS scores. The baseline clinical Among women who suffer from otherwise unexplained chronic pelvic pain, venography studies have shown that pelvic characteristics of this group are listed in Table II . All patients were cycling regularly, suggesting a normal hormonal milieu.
congestion syndrome is responsible for the incapacitating chronic pelvic pain in many cases (Beard et al., 1986) . Symptoms None of them was using oral contraception, and none used oral contraceptives after the treatment as an adjunctive measure.
of pelvic congestion syndrome include deep dyspareunia, congestive dysmenorrhoea, post-coital pain, and a dull chronic Randomization resulted in statistically similar baseline characteristics.
pelvic pain with sharp exacerbation triggered by postural changes. Pain can sometimes be lessened simply by lying down The first evaluation was performed to determine subjective outcome data at the end of treatment, immediately after the and elevating the legs. The pain of pelvic congestion syndrome is typically aggravated by states of pelvic vessel engorgement first menstrual period. Initially, results seemed to indicate a (many hours of standing or working in a sitting position, In this study, the following points were postulated: (i) Pelvic congestion syndrome is a distinct clinical entity. (ii) As once premenstrually, and most notably after coitus). Tenderness of the ovarian point (the junction of the upper and middle thirds believed, the syndrome was not a stress disorder, and the deprived psychological status of these patients was the result of of a line drawn between the umbilicus and anterior superior iliac spine) and directly elicited ovarian tenderness are well described unidentified, unclear origin of their pain and undertreatment of the syndrome, and that the situation was reversible by using the signs of this condition, other than tenderness of the uterus, posterior parametrium and uterosacral ligaments (Beard et al., appropriate treatment. (iii) Sexual satisfaction can be regained by appropriate medical treatment. (iv) If a hypo-oestrogenic 1986, 1988). Diagnosis of this condition can sometimes be achieved using laparoscopy, transvaginal ultrasonography (with/ hormonal milieu can be created by the most effective medical modality, the outcome of this treatment will be more effective without colour Doppler equipment), magnetic resonance imaging and computed tomography (Desimpelaere et al., 1999) , than other studied medical regimens. Although controversy persists, we believe that pelvic but none of these methods can delineate the detailed pathological anatomy of pelvic varicose veins as accurately as pelvic congestion syndrome is a distinct clinical entity. In the present cohort of 148 chronic pelvic pain patients, pure pelvic congestion peruterine venography. Venous stasis can also be studied using fluoroscopic peruterine venography. Modalities other than pelvic was identified in 30% of patients. These results confirmed the findings of others (Beard et al., 1986 (Beard et al., , 1988 in that only a single venography (in their current state) can be used only as screening modalities as they have variable specificity and sensitivity.
case of minimal pelvic congestion was found among a group of asymptomatic patients, whereas 15% of variable degree congesOne hallmark of pelvic congestion syndrome is its disappearance after the menopause (Beard et al., 1986 (Beard et al., , 1988  tion was detected in a group patients with organic pathology demonstrable by laparoscopy or ultrasonography (Beard et al., Porpora and Gomel, 1997) . As induced hypo-oestrogenic stages or venoconstriction and/or occlusion of varicose veins 1986, 1988) . Among those women who were sexually active, asymptomatic, and requesting tubal ligation, not one case of (by medical or surgical as well as interventional radiological treatment) results in ameloriation of symptoms, this syndrome is severe pelvic congestion was identified. While this was the main conclusion drawn from this patient group, a low pelvic symptom suspected to occur as a result of gonadal dysfunction, cooperative with mechanical factors (Farquhar et al., 1989; Reginald et al., score, and a low HADS score in addition to higher scores of sexual functioning were noted. Typical examples of concomitant 1989; Venbrux and Lambert, 1999) . Medical treatment of pelvic congestion includes progestins, danazol, phelobotonics pelvic congestion syndrome are shown in Figure 2a -c, and in these cases it is believed that pelvic congestion occurs secondary and non-steroidal anti-inflammatory drugs (Charles, 1995) . In addition to these agents, GnRH agonists combined with HRT to tissue distortion and destruction and results in altered pathways of venous drainage. It cannot be assumed that, when pelvic have been used for the treatment of this syndrome (Gangar et al., 1993) . These authors reported that, after a treatment period of 4 pathology is found at laparoscopy in women with chronic pelvic pain, the two are necessarily related. The cause of pain (organic months, combined goserelin and hormone replacement therapy was not effective in treating pelvic congestion syndrome, despite pathology or congestion) in concomitant pelvic congestion is unclear (Beard et al., 1991) . To quote Beard and his co-authors, effective ovarian suppression. However, these authors have stated that 'it is also possible that relief of pain and congestion 'What is certain, is that pelvic congestion in the absence of endometriosis, does cause pain, whereas the converse is not is not obtained because the treatment period of four months is not sufficiently long'. In a survey of the literature, not a single proven' (Beard et al., 1991) . This statement may hold true for the PID-associated pelvic pain patient shown (Figure 2a and report could be found on the use of GnRH analogues only, for 6 months, for the treatment of pelvic congestion syndrome. b). Further clinical investigations are necessary in concomitant pelvic congestion syndrome. However, during the study period Nonetheless, the use of GnRH analogues was highly attractive in the present study because they had very often been used during the organic pathologies were treated irrespective of the venography scores. the past decades to suppress ovarian function, and to create an artificial menopause for a variety of gynaecological disorders of Patients with pure pelvic congestion syndrome had higher HADS scores than any other pathology, but their scores variable duration. The other well-studied compound used to suppress ovarian function, namely MPA, produced a variable responded to medical treatment and reassuring clinical care. It was stated that psychological disturbances may exist in this effect that in the main was short-lasting (Farquhar et al., 1989; Reginald et al., 1989; Adams et al., 1990) . Other treatment syndrome; even psychotherapy was recommended and tested in a prospective randomized manner (Farquhar et al., 1989) . Sexual modalities of pelvic congestion syndrome were simply mechanical, by the use of a variety of techniques including abuse history, experience of insecure family life in childhood and psychological stressors were all claimed in the aetiology extraperitoneal or laparoscopic ligation of pelvic varices and/or ovarian veins, embolization of varices and/or ovarian veins by of this syndrome (Farquhar et al., 1989; Porpora and Gomel, 1997) . Although a high score of anxiety and depression was interventional radiological procedures, and hysterectomy with bilateral adnexectomy (Hobbs, 1990; Mathis et al., 1995;  noted in the present pelvic congestion syndrome patients, it is believed that the chronic pelvic pain of the condition is the result Capasso et al., 1997; Cordts et al., 1997; Venbrux and Lambert, 1999) . Even though definitive surgery (hysterectomy with of varicosities, while the greater anxiety and depression of the patient is a natural human response to an undiagnosed, unclear bilateral adnexectomy) is an effective treatment (both in terms of pain relief and restoration of normal sexual function), it must aetiology of debilitating chronic pain. Psychotherapy was not used instead of any proposed treatment for aetiology, and a always remain as the last option (Beard et al., 1991) .
significant reduction of HADS scores accompanied by an
The human sexual cycle is characterized by vascular engorgement; in an already incompetent vascular system this objective reduction in the diameters of pelvic veins was noted. It has been shown that surgical, interventional radiological treatengorgement leads to venous stasis characterized by dsypareunia and the long-lasting post-coital ache of pelvic congestion ments, venoconstrictors and MPA all reduce the diameter of veins and ameloriate symptoms, irrespective of the psychosyndrome. Post-coital pain is the most common reason for abandonment of sexual activity in pelvic congestion syndrome logical status of the patient (Reginald et al., 1987; Mathis et al., 1995; Venbrux and Lambert 1999) . In the present study, the (Beard et al., 1988) . Indeed, it has been shown that correct treatment of pelvic congestion syndrome improves sexual GnRH analogue goserelin acetate induced a statistically more profound reduction in objective venogram scores compared with satisfaction (Farquhar et al., 1989; Hobbs, 1990; Beard et al., 1991; Sichlau et al., 1994) . In the present study, in patients with MPA, and also resulted in a more profound reduction in anxiety and total scores of HADS. The depression subscale was also pelvic congestion syndrome a strikingly low rSSRS baseline score was found compared with other scores, indicating the reduced significantly in both groups, in parallel with venography score reduction. These results indicate that the symptoms of negative impact of varices on sexual functioning, and treatment in both study arms was effective in restoring the scores. Again, this syndrome cannot be regarded as a somatization because diminution of vein diameters improves psychological status by goserelin, by achieving a significantly greater reduction in pelvic venogram scores, had a more favourable impact on sexual satisameliorating the pain itself.
Somatization is simply the persistent, unexplained medical faction of patients than did MPA. It has been shown previously that any treatment modality capable of decreasing either vein symptoms, and may be associated with current and lifetime depression; moreover, it is the construct that links apparently diameters or venography scores will ameloriate most of the symptomatology of pelvic congestion syndrome. As goserelin dissimilar disorders. Somatization is frequently considered as a maladaptive coping strategy gained in the early family life.
was more effective than MPA in reducing the venogram scores, the patients' symptomatology regarding sexual functioning Anxiety and depression on the other hand can have physical symptoms. Chronic pelvic pain without any anatomical basis improved more favourably in the goserelin arm. The cause of pelvic congestion is speculative; it may be may be seen in depression; it can be a somatization disorder, or the presence of a co-morbid anxiety or depression may render either oestrogen-dependent or simply mechanical, but it is most probably cooperative. Currently, it is known that in the patient at risk of somatic amplification. It has been shown that 70-80% of psychiatric patients initially have physical symptoms order to overcome the symptomatology, an effective treatment should reduce the diameters of veins and improve venous (Walker, 1997) .
Despite the fact that the terms 'illness' and 'disease' are drainage of the pelvis (Hobbs, 1990) . Long-term benefits of MPA (30 mg/day for 4-6 months) have been demonstrated frequently used interchangeably, medical sociologists have made useful distinctions between these concepts (Walker, previously, and the authors of these studies have used MPA to produce a hormonal milieu of hypo-oestrogenism and a reduced 1997). Disease describes the objective, physiological changes associated with organic pathology and physical signs. In end-organ response to oestrogens (Farquhar et al., 1989; Reginald et al., 1989; Adams et al., 1990) . These authors were successpatients with pelvic congestion, these are venography scores and ovarian point tenderness, as well as enlargement of the uterus ful in reducing both venogram scores and pain using this regimen, and considered MPA in the above-mentioned doses and cystic ovaries. Illness, on the other hand, refers to subjective decrements in emotional, role, social and occupational functo represent first-line therapy of pelvic congestion syndrome (Farquhar et al., 1989) . In the published literature it was noted tioning. Thus, the patient can complain of coital-post-coital pain and abandonment of sexual life, and may also complain of the that in some cases, unresponsiveness to MPA was the result of an unsatisfactory hypo-oestrogenic state caused by the drug marital consequences of this role. This distinction is very useful in characterizing the process of somatization (Walker, 1997) .
itself (Farquhar et al., 1989) . In the present study, the efficiency of goserelin compared with MPA was tested in a prospective, Patients can have disease with illness (such as those in the pure pelvic congestion group, in the organic pathology group), randomized manner. In the present authors' opinion the most important feature of pelvic congestion syndrome is its patients can have illness without organic disease, i.e. somatization (such as those referred for psychiatry), and patients can disappearance after menopause. However, it is unlikely that a temporary artificial menopause of 6 months will achieve permanhave disease without illness (this has been sought in the tube ligation group, where pelvic congestion might have been a ent cure of the syndrome. However, we postulated that the most effective suppression of ovarian function would have a longernormal finding in parous, sexually active women).
Accordingly, in the present study no significant pelvic lasting effect on the syndrome, and this was the reason for choosing an arbitrary 1-year interval after treatment. In fact, 1 congestion was noted in the tube ligation group. Eight patients were referred for psychiatry, despite their initial complaint being year was longer than the term reported earlier regarding MPA. Goserelin, with its natural pharmacological consequence of chronic pelvic pain. It was not possible to diagnose pelvic congestion objectively in 47 patients who, unfortunately, had creating hypo-oestrogenism, was more effective than MPA, and also found to reduce more effectively the pelvic venogram deprived psychological and sexual status in terms of HADS and rSSRS scores when compared with other organic pathologies.
scores. Therefore, goserelin was better to ameliorate symptoms, reduce patients' anxiety and improve sexual satisfaction during However, after appropriate treatment these patients responded favourably both as a disease (venography score improvement) the long-term treatment of pelvic congestion syndrome. According to our data, both agents improve the subjective outcome of or as an illness (mood and sexual functioning improvement). tive studies with larger patient population sizes are necessary to provide such information.
